查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1630942

自体细胞治疗市场规模、份额、趋势分析报告：按治疗类型、治疗领域、地区、细分预测，2025-2030 年

Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type ( Autologous Therapies, Non-Stem Cell Therapies, Non-Stem Cell Therapies), By Therapeutic Area (Oncology, Dermatology), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

自体细胞治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球自体细胞治疗市场规模预计到2030年将达到182.3亿美元，2025年至2030年复合年增长率为22.01%。

癌症、神经退化性疾病疾病、自体免疫疾病、自体免疫疾病和整形外科等疾病和残疾负担的增加是推动市场需求的因素。同样，由于这些治疗方法是从患者来源的细胞开发而来的，有助于再生体内受损的组织，因此降低自体细胞疗法排斥的风险是市场发展的关键驱动力。

在 COVID-19 疫情期间，市场面临各种挑战，患者出于安全考虑被迫待在家中。影响市场成长的因素包括製造障碍和医院病患流入量的减少。然而，在新冠疫情之后，随着 FDA 批准的多种治疗手段取得新进展，市场需求也有所增加。

2020 年 4 月，临床阶段生物技术公司 Hope Biosciences 宣布了 HB-adMSCs（Hope Bioscience 的自体脂肪间质间质干细胞）在提供对COVID-19 的免疫支持方面的有效性和安全性。了II期临床试验评估2020年6月，凯西集团与Holoclar转让公司达成协议。 Holoclar 是一种针对眼表烧伤患者的自体干细胞治疗方法。该交易将使两家公司专注于各自的策略目标，即加速获得罕见疾病的治疗方法。

自体细胞治疗市场报告重点

  • 2024 年非干细胞治疗领域占据市场主导地位，份额为 97.41%。这一巨大份额归因于多种因素，包括 CAR-T 细胞疗法研究的扩大和临床试验的增加。
  • 预计肿瘤学领域将在 2024 年占据 88.55% 的市场占有率。 CD19 针对 CAR T 细胞可帮助治疗急性淋巴性白血病(ALL) 患者，并达到高完全缓解率和长期缓解率。
  • 2024年北美自体细胞治疗市场占有57.88%的份额。由于 BrainStorm Cell Therapeutics 和 Bristol Myers Squibb 等大多数大公司都在该地区开展业务，因此市场竞争非常激烈。
  • 预计预测期内亚太地区自体细胞治疗市场将大幅成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章自体细胞治疗市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 自体细胞治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL 分析
    • 管道分析
    • COVID-19影响分析

第四章 治疗类型业务分析

  • 全球自体细胞治疗市场：治疗类型细分仪表板
  • 全球自体细胞治疗市场：治疗类型变化分析
  • 按治疗类型
  • 干细胞治疗
    • 2018 年至 2030 年干细胞治疗市场估计与预测
    • 骨髓、血液和脐带来源的干细胞
    • 脂肪来源细胞
    • 其他的
  • 非干细胞疗法
    • 2018 年至 2030 年非干细胞疗法市场估计与预测
    • T细胞治疗
    • 其他的

第五章 治疗领域业务分析

  • 全球自体细胞治疗市场：治疗领域仪表板
  • 全球自体细胞治疗市场：治疗领域变迁分析
  • 按治疗领域分類的收益
  • 肿瘤学
    • 2018 年至 2030 年肿瘤学市场估计与预测
  • 心血管疾病
    • 2018 年至 2030 年心血管疾病市场估计与预测
  • 肌肉骨骼疾病
    • 肌肉骨骼疾病市场估计与预测 2018-2030
  • 皮肤科
    • 2018 年至 2030 年皮肤科市场估计与预测
  • 其他的
    • 2018-2030 年其他市场估计与预测
    • 2018-2030 年其他市场估计与预测

第六章 区域经营分析

  • 区域控制面板
  • 市场规模、预测趋势分析，2018-2030 年：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 瑞士
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
  • 世界其他地区
    • 2018 年至 2030 年世界其他地区市场估计与预测

第七章 竞争格局

  • 公司分类
  • 2024 年主要企业定位分析
  • 公司简介/上市公司
    • Bluebird bio, Inc.
    • Novartis AG.
    • Holostem SRL
    • Pharmicell Co. Inc
    • Gilead Sciences, Inc.（Kite）
    • Bristol Myers Squibb Company
    • Johnson &Johnson（Janssen Global Services, LLC.）
    • JW Therapeutics
    • Vertex Pharamaceuticals Inc.
    • Autolus therapeutics
Product Code: GVR-4-68040-017-2

Autologous Cell Therapy Market Growth & Trends:

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights:

  • The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.
  • The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.
  • The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.
  • Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic Area
    • 1.2.2. Therapy Type
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of chronic and degenerative diseases
      • 3.2.1.2. Reduced risk of autologous cell therapy rejection
      • 3.2.1.3. Growing demand for personalized medicine
      • 3.2.1.4. Increasing investments in research & development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of therapy and limited affordability
      • 3.2.2.2. Stringent regulatory requirements and long approval timelines
  • 3.3. Autologous Cell Therapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. COVID-19 Impact Analysis

Chapter 4. Therapy Type Business Analysis

  • 4.1. Global Autologous Cell Therapy Market: Therapy Type Segment Dashboard
  • 4.2. Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
  • 4.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapy Type (USD Million)
  • 4.4. Stem Cell Therapies
    • 4.4.1. Stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. BM, Blood, & Umbilical Cord-derived Stem Cells
      • 4.4.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Adipose-Derived Cells
      • 4.4.3.1. Adipose-Derived Cells market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-stem Cell Therapies
    • 4.5.1. Non-stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. T-Cell Therapies
      • 4.5.2.1. T-Cell Therapies market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.2. CAR T Cell Therapy
        • 4.5.2.2.1. CAR T cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.3. T Cell Receptor (TCR)-based
        • 4.5.2.3.1. T Cell Receptor (TCR)-based market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Others
      • 4.5.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Global Autologous Cell Therapy Market: Therapeutic Area Dashboard
  • 5.2. Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
  • 5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiovascular Diseases
    • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Musculoskeletal Disorders
    • 5.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Dermatology
    • 5.7.1. Dermatology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. Target disease prevalence
      • 6.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Target disease prevalence
      • 6.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. Target disease prevalence
      • 6.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Target disease prevalence
      • 6.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Switzerland
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Target disease prevalence
      • 6.4.3.5. Switzerland market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Target disease prevalence
      • 6.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Target disease prevalence
      • 6.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Target disease prevalence
      • 6.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. South Korea
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Target disease prevalence
      • 6.5.4.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Rest of the World
    • 6.6.1. Rest of the world market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Key Company Position Analysis, 2024
  • 7.3. Company Profiles/Listing
    • 7.3.1. Bluebird bio, Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Novartis AG.
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Holostem S.R.L
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Pharmicell Co. Inc
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Gilead Sciences, Inc. (Kite)
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Bristol Myers Squibb Company
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Johnson & Johnson (Janssen Global Services, LLC.)
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. JW Therapeutics
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Vertex Pharamaceuticals Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Autolus therapeutics
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 Global Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 3 Global Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 4 Global Autologous Cell Therapy Market By Region, 2018 - 2030 (USD Million)
  • Table 5 North America Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
  • Table 6 North America Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 7 North America Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 8 U.S. Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 10 Canada Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 12 Europe Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 15 Germany Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 16 Germany Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 17 UK Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 18 UK Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 19 Switzerland Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Switzerland Autologous Cell Therapy MarketBy Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24 China Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 25 China Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 26 Japan Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 27 Japan Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 28 India Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 29 India Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 30 South Korea Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 31 South Korea Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 32 Rest Of The World Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 33 Rest Of The World Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Autologous Cell Therapy Market, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 PESTEL Analysis
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Global Autologous Cell Therapy Market: Therapy Type Key Takeaways
  • Fig. 12 Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
  • Fig. 13 Global Autologous Cell Therapy Market For Autologous Stem-Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Autologous Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 15 Global Autologous Cell Therapy Market For Adipose Derived Cells, 2018 - 2030 (USD Million)
  • Fig. 16 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
  • Fig. 17 Global Autologous Cell Therapy Market For Autologous Non-Stem Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 18 Global Autologous Cell Therapy Market For T-Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Autologous Cell Therapy Market For CAR T Cell Therapy, 2018 - 2030 (USD Million)
  • Fig. 20 Global Autologous Cell Therapy Market For T Cell Receptor (TCR)-Based, 2018 - 2030 (USD Million)
  • Fig. 21 Global Autologous Cell Therapy Market For Other Autologous Non Stem-Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 22 Global Autologous Cell Therapy Market: Therapeutic Area Key Takeaways
  • Fig. 23 Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
  • Fig. 24 Global Autologous Cell Therapy Market For Oncology, 2018 - 2030 (USD Million)
  • Fig. 25 Global Autologous Cell Therapy Market For Cardiovascular Disease (CVD), 2018 - 2030 (USD Million)
  • Fig. 26 Global Autologous Cell Therapy Market For Musculoskeletal Disorders, 2018 - 2030 (USD Million)
  • Fig. 27 Global Autologous Cell Therapy Market For Dermatology, 2018 - 2030 (USD Million)
  • Fig. 28 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Outlook, 2024 & 2030
  • Fig. 30 North America Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S.Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 35 UK Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 36 Switzerland Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 37 Asia Pacific Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 39 China Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 40 India Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 42 Rest Of The World Autologous Cell Therapy Market, 2018 - 2030 (USD Million)